← Leaderboards
Shawn Patrick Zinnen
Aurora Oncology, Inc.
$4,227,093
Attributed
$5,674,512
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2013–23$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$5,674,512 · 5
By mechanism
R44$4,435,964 · 2
R43$1,238,548 · 3
Top collaborators
- Mike Glode3 shared
- Douglas H Thamm2 shared
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsMalignant NeoplasmsCancer PatientToxic EffectDesignDoseCanis FamiliarisSafetyTissuesDrug KineticsCell KillingNovel StrategiesLeadTherapeutic AgentsIn VivoRouteDrug DesignSafety StudyBiological ModelsGrantSmall Business Innovation Research GrantAmputationLesionIbandronate
Grant awards (11)
DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer$999,955
R44 · FY2023 · CA
DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer$1,000,745
R44 · FY2020 · CA
Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II$860,229
R44 · FY2018 · CA · contact PI
DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer$299,937
R44 · FY2018 · CA
Bone Targeted Antibiotics$294,202
R43 · FY2018 · AI · contact PI
Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II$136,623
R44 · FY2018 · CA · contact PI
Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II$1,138,475
R44 · FY2017 · CA · contact PI
Bone Targeted Antibiotics$300,000
R43 · FY2017 · AI · contact PI
Novel Bone-Targeting Combination Therapy for Osteosarcoma$301,877
R43 · FY2016 · CA · contact PI
Novel Vitamin B6 based prodrugs of gemcitabine$100,957
R43 · FY2014 · CA · contact PI
Novel Vitamin B6 based prodrugs of gemcitabine$241,512
R43 · FY2013 · CA · contact PI